Dermata Therapeutics, Inc. (DRMA)
0.8699
+0.01
(+1.16%)
USD |
NASDAQ |
Oct 20, 16:00
0.85
-0.02
(-2.29%)
After-Hours: 06:22
Dermata Therapeutics Enterprise Value : -0.914M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | -0.914M |
| October 19, 2026 | -0.9542M |
| October 16, 2026 | -0.9538M |
| October 15, 2026 | -0.7527M |
| October 14, 2026 | -1.745M |
| October 13, 2026 | -0.9542M |
| October 12, 2026 | -0.8347M |
| October 09, 2026 | -0.3103M |
| October 08, 2026 | -0.1092M |
| October 07, 2026 | 0.092M |
| October 06, 2026 | 0.1322M |
| October 05, 2026 | 0.0517M |
| October 02, 2026 | 0.0316M |
| October 01, 2026 | 0.0517M |
| September 30, 2026 | 0.0115M |
| September 29, 2026 | 0.1322M |
| September 28, 2026 | 0.092M |
| September 25, 2026 | 0.1724M |
| September 24, 2026 | 0.2931M |
| September 23, 2026 | 0.092M |
| September 22, 2026 | 0.2126M |
| September 21, 2026 | 0.2126M |
| September 18, 2026 | 0.2528M |
| September 17, 2026 | 0.2528M |
| September 16, 2026 | 0.2126M |
| Date | Value |
|---|---|
| September 15, 2026 | 0.1322M |
| September 14, 2026 | 0.2126M |
| September 11, 2026 | 0.3735M |
| September 10, 2026 | 0.4137M |
| September 09, 2026 | 0.4539M |
| September 08, 2026 | 0.6148M |
| September 04, 2026 | 0.4539M |
| September 03, 2026 | 0.5344M |
| September 02, 2026 | 0.7355M |
| September 01, 2026 | 0.8159M |
| August 31, 2026 | 0.7757M |
| August 28, 2026 | 0.9768M |
| August 27, 2026 | 1.460M |
| August 26, 2026 | 2.063M |
| August 25, 2026 | 2.505M |
| August 24, 2026 | 2.143M |
| August 21, 2026 | 1.299M |
| August 20, 2026 | 1.138M |
| August 19, 2026 | 1.500M |
| August 18, 2026 | 1.339M |
| August 17, 2026 | 1.460M |
| August 14, 2026 | 1.460M |
| August 13, 2026 | 1.902M |
| August 12, 2026 | 1.138M |
| August 11, 2026 | -0.0689M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 260.39M |
| Perspective Therapeutics, Inc. | 29.48M |
| MiMedx Group, Inc. | 497.78M |
| ABVC BioPharma, Inc. | 28.74M |
| Agilent Technologies, Inc. | 50.97B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.967M |
| Total Expenses (Quarterly) | 2.967M |
| EPS Diluted (Quarterly) | -0.7377 |
| Earnings Yield | -504.2% |
| Normalized Earnings Yield | -504.24 |